肉的治疗潜力:专注于细胞和分子机制
Giuseppe Caruso1,2, Lucia Di Pietro1,3, Vincenzo Cardaci3,4
1Department of Drug and Health Sciences, University of Catania, Catania, Italy.
Current research in pharmacology and drug discovery
|July 13, 2023
概括
卡诺辛是一种二聚,具有抗氧化,抗炎和抗聚合作用. 它显示了对2型糖尿病,心血管疾病和阿尔茨海默氏症的治疗潜力.
科学领域:
- 生物化学和分子生物学
- 神经科学是一个神经科学.
- 心血管研究研究心血管研究
- 内分泌学 在内分泌学.
背景情况:
- 肉是一种内源性二,在具有高氧化代谢的组织中发现,如肌肉和大脑.
- 超过50年的广泛研究强调了肉素的多模式作用:抗聚合物,抗氧化剂和抗炎作用.
- 常见的致病机制将2型糖尿病 (T2DM),心血管疾病 (CVD) 和神经退行性疾病 (例如阿尔茨海默氏症 - AD) 联系起来,包括氧化应激,炎症和蛋白质聚合.
研究的目的:
- 审查卡诺辛在T2DM,CVD和AD中的保护潜力.
- 探索卡诺辛在共同致病途径的疾病中的作用.
- 评估卡诺辛的治疗前景,特别是在患有心血管疾病和AD风险的T2DM患者中.
主要方法:
- 关于肉素的体外,体内和临床研究的全面审查.
- 分析了卡诺辛的药理动力学特征和作用机制.
- 在T2DM,心血管疾病和神经退行性疾病的实验模型中检查卡诺辛的疗效.
主要成果:
- 卡诺辛具有显著的抗氧化,抗炎和抗聚合性质.
- 它的多模式作用在T2DM,CVD和AD的实验模型中是有效的.
- 卡诺辛既具有系统性益处 (抗炎,抗氧化剂),也具有中枢神经系统作用 (抗聚合剂,神经保护性).
结论:
- 卡诺辛的广泛的药理学特征支持其在T2DM,CVD和AD的治疗潜力.
- 它对抗氧化应激,炎症和聚合的能力是其保护作用的关键.
- 肉代表着一个有前途的治疗途径,特别是在T2DM患者,如心血管疾病和认知能力下降的风险增加.
更多相关视频
11:47Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
Published on: January 22, 2017
10.6K
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
2.6K
相关概念视频
01:46Electron Transport Chain: Complex I and II
14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:26Targets for Drug Action: Overview
6.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.4K
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K